CBT After Esketamine Boosts Depression Outcomes in Trial

New Trial: Pairing CBT With Esketamine Outperforms Esketamine Alone

One of the most persistent questions in ketamine-based psychiatry is whether these treatments work best as standalone interventions or as a bridge to other care. A new randomized controlled trial — the CBT-ENDURE study, published in the Journal of Clinical Psychiatry in May 2026 — offers meaningful data in response. The trial found that adding a structured 16-week course of cognitive behavioral therapy (CBT) after esketamine treatment led to significantly greater reductions in both suicidal ideation and depression severity compared to esketamine treatment alone.

The trial enrolled a high-acuity population: adults with major depressive disorder (MDD) who also presented with active suicidal ideation — a group for whom fast-acting treatments are urgently needed and sustained recovery is notoriously difficult to maintain. That this combination produced measurable, lasting benefits in this population makes the findings especially notable. You can read the original study at the Journal of Clinical Psychiatry.

What the Study Found — and Why the Design Matters

After completing an initial esketamine series, participants were randomized to one of two groups: 16 weeks of structured CBT, or no additional psychotherapy. The CBT group showed greater improvement on both primary outcome measures — suicidal ideation severity and overall depression scores — than those who received esketamine alone.

The study design carries real weight here. This is a randomized controlled trial — the gold standard in clinical research — which means the results are considerably more reliable than the observational studies and open-label reports that have dominated ketamine research until recently. Randomization reduces the risk that the CBT group simply happened to include less severely ill patients, giving researchers (and readers) greater confidence that CBT itself is contributing to better outcomes.

One important distinction worth flagging: this trial used esketamine (brand name Spravato), an FDA-approved nasal spray specifically indicated for treatment-resistant depression and MDD with suicidal ideation. Esketamine is administered in certified clinical settings with mandatory post-dose monitoring. It is pharmacologically related to — but not identical to — the IV racemic ketamine offered off-label at many standalone ketamine clinics. The evidence base and regulatory frameworks for these two treatments differ, though both are sometimes discussed under the broader umbrella of "ketamine therapy."

Why Combining CBT With Ketamine Makes Biological and Clinical Sense

The emerging hypothesis in the field is that ketamine and esketamine create a temporary window of heightened neuroplasticity — a period during which the brain may be unusually receptive to learning, behavioral change, and cognitive reframing. CBT, which is specifically designed to identify and restructure the distorted thought patterns and avoidance behaviors that sustain depression and suicidal thinking, may be uniquely effective during this window. Put simply: esketamine may lift the floor rapidly, while CBT helps build new cognitive architecture above it.

The suicidal ideation findings deserve particular attention. Esketamine holds an FDA breakthrough therapy designation in part because of its rapid antisuicidal effects — a meaningful advantage over standard antidepressants that can take weeks to show results. But suicidal ideation is complex and prone to recurrence. The CBT-ENDURE results suggest that CBT may extend and deepen the acute antisuicidal gains made during the esketamine phase, helping patients hold those gains over time.

The trial name itself — ENDURE — explicitly flags relapse prevention as the goal. This framing matters. Esketamine's effects are time-limited; the biological window closes. CBT equips patients with durable skills that remain active after treatment ends. These two mechanisms are complementary rather than redundant, which is exactly what the trial outcomes reflect.

Practical Implications for Patients and Families

Ask about the plan after the acute series. A thoughtful ketamine provider should be able to articulate what happens once the initial infusion or nasal spray series ends. Do they coordinate with a therapist? Do they offer therapy in-house? Or does that piece fall entirely to you? This study suggests that follow-through with structured CBT in the months after esketamine may meaningfully reduce relapse risk — making it a legitimate factor in provider selection.

This is additive evidence, not disqualifying. The trial showed that esketamine alone produced real improvements; CBT amplified those improvements. If therapy is not accessible to you right now, esketamine is not without benefit. But the combination appears to deliver more durable outcomes for those who can access both.

Consider access and commitment honestly. The CBT component here was 16 weeks — a substantial commitment requiring an engaged, skilled therapist, consistent attendance, and active participation. For many patients, finding and affording a qualified CBT therapist remains a real obstacle. The clinical evidence is promising; the practical infrastructure to deliver it reliably at scale is still catching up.

Generalizability has limits. CBT-ENDURE enrolled specifically patients with both MDD and active suicidal ideation. The results may not apply identically to patients pursuing ketamine for treatment-resistant depression without suicidal ideation, though the underlying neuroplasticity rationale supports combination approaches broadly. As always, individual clinical circumstances vary — this evidence informs conversations with your care team, but does not replace them.